US Patent
US11160786 — Rapid disperse dosage form
Formulation · Assigned to Aprecia Pharmaceuticals LLC · Expires 2034-03-14 · 8y remaining
Vulnerability score
42/100
Strong — defensible against typical IPR challenges
What this patent protects
Aprecia Pharmaceuticals LLC has patented a method for making a rapidly dispersing dosage form of a water-soluble drug that dissolves in under 15 seconds.
USPTO Abstract
A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.
Drugs covered by this patent
- Keppra (levetiracetam) · Generic (originally UCB Pharma)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.